- Conditions
- Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
- Interventions
- Placebo, EG-501
- Drug
- Lead sponsor
- Evergreen Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 9,004
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cytomegalovirus Infection
- Interventions
- Brincidofovir, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Genetics Disease, Genetics/Birth Defects, Genetic Predisposition to Disease
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Days to 99 Years
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
- Conditions
- Endometrial Cancer
- Interventions
- Navtemadlin, Navtemadlin Placebo
- Drug
- Lead sponsor
- Kartos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 19
- States / cities
- Vallejo, California • Atlanta, Georgia • Savannah, Georgia + 16 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- FB704A, Placebo
- Drug
- Lead sponsor
- Fountain Biopharma Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- Polyphenon E
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Volunteers
- Interventions
- 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Spinal Cord Injuries
- Interventions
- 5HTP, L-DOPA, Placebo oral tablet, Carbidopa
- Drug
- Lead sponsor
- Jessica M D'Amico
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- SGLT-2 inhibitor, SGLT2 inhibitor
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 8 Years to 18 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- NF1, Cutaneous Neurofibroma, Monotherapy
- Interventions
- Mirdametinib
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Peyronie's Disease (PD)
- Interventions
- Xiaflex®, Aveed
- Drug
- Lead sponsor
- Men's Health Boston
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Melanoma, Carcinoma, Non-Small- Cell Lung
- Interventions
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Rheumatoid Arthritis, Interstitial Lung Disease
- Interventions
- Research Testing Performed (Laboratory), Information Collected as Standard of Care, Research Testing Performed
- Genetic · Diagnostic Test · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 4
- States / cities
- San Francisco, California • Aurora, Colorado • Kansas City, Kansas + 1 more
- Conditions
- Healthy
- Interventions
- Controlled-Release Oxycodone Hydrochloride 40 mg tablet, OxyContin® 40 mg tablet
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Rilpivirine, Placebo
- Drug
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Newark, New Jersey • The Bronx, New York
- Conditions
- Lumbar Disc Herniation, Degenerative Disc Disease, Spondylolisthesis
- Interventions
- Morphine, Epinephrine, naropin
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acute Respiratory Failure, Intubation Complication
- Interventions
- intravenous crystalloid fluid, 500 mL
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Jefferson, Louisiana • New Orleans, Louisiana + 4 more
- Conditions
- Epilepsy
- Interventions
- Lamotrigine Generic "A", Lamotrigine generic "B"
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Des Moines, Iowa • Kansas City, Kansas + 5 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 29
- States / cities
- Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
- Conditions
- HIV, Depression, HIV Infections
- Interventions
- Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD), Life-steps adherence treatment, Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Providence, Rhode Island
- Conditions
- Schizophrenia
- Interventions
- Oxytocin, Placebo, Control
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Labor Induction
- Interventions
- Amniotomy, Foley Catheter, Misoprostol
- Procedure · Device · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Tumor
- Interventions
- Para-toluenesulfonamide Injection (PTS)
- Drug
- Lead sponsor
- PTS International Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Epstein-Barr Virus Infection
- Interventions
- mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more